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Background: Microfibrillar-associated protein 4 (MFAP4) is a matricellular glycoprotein that co-
localises with elastic fibres and is highly expressed in the lungs. The aim of this study was to
test the hypothesis that plasma MFAP4 (pMFAP4) reflects clinical outcomes in chronic obstruc-
tive pulmonary disease (COPD).550 3932.
.sdu.dk (G.L. Sorensen).
14.06.003
hts reserved.
MFAP4 variation in chronic obstructive pulmonary disease 1337Chronic obstructive
pulmonary disease;
Acute exacerbation of
COPD;
BODE index;
Modified Medical
Research Council
scoreMethods: pMFAP4 was measured by an AlphaLISA immunoassay in stable COPD (n Z 69) at
baseline and at follow-up until 24 months after inclusion and in acute exacerbations of COPD
(AECOPD) (n Z 14) at baseline and until 6 months after inclusion.
Results: The majority of patients (89%) were in GOLD II and III. Multiple linear regressions
showed positive associations between pMFAP4 and the Global initiative for Obstructive Lung
Disease (GOLD) grade (p Z 0.01), modified Medical Research Council score (p < 0.0001) and
BODE index (p Z 0.04). Negative associations were found with 6-min walking distance
(pZ 0.04) and bronchodilator-induced reversibility (pZ 0.02). The pMFAP4 levels varied less
than 25% between the baseline and a 3 month follow-up in 83% of the patients. The pMFAP4
levels appeared unaffected in the acute phase of severe AECOPD but rose to an increased sta-
ble level within one month after hospitalization.
Conclusion: Increased pMFAP4 was associated to the severity in COPD and has the potential to
serve as a stable disease biomarker. This observation warrants confirmation in a larger longi-
tudinal COPD population.
ª 2014 Elsevier Ltd. All rights reserved.Background
Chronic obstructive pulmonary disease (COPD) is charac-
terised by pulmonary emphysema and a progressive airflow
limitation caused by small airway disease [1]. Emphysema
results from the degradation of the lung parenchyma,
partly due to an inflammation induced protease-
antiprotease imbalance [2].
Airflow is quantified using forced expiratory volume in
one second (FEV1) and FEV1 is currently the only validated
biomarker in COPD. However, FEV1 is poorly correlated with
symptom burden and outcomes in COPD, which makes it an
inadequate surrogate marker of disease activity, a poor
predictor of disease progression and an ineffective tool for
the evaluation of treatment responses [3]. Thus, there is a
pressing need for new, non-invasive and cost effective
biomarkers in COPD [4].
Extracellular matrix turnover products have been sug-
gested as alternative markers of emphysema development
and respiratory disease activity [5e7], and microfibrillar-
associated protein 4 (MFAP4/MAGP-36) is a matricellular
glycoprotein highly expressed in the lung [8]. Immuno-
histochemistry and immunogold electron microscopy have
demonstrated that MFAP4 is colocalised with microfibrils
in elastic fibres in pulmonary blood vessels and in the
alveolar septae [9,10]. MFAP4 is moreover increased in
cirrhotic liver disease [11]. MFAP4 binds to collagen,
elastin and the collagen-like regions of pulmonary sur-
factant proteins A (SP-A) and D (SP-D) [9,10,12] and is
suggested with a protective role in photodamaging of the
skin through the regulation of metalloproteinase expres-
sion [13].
The specific objectives of this pilot-study testing the
hypothesis that MFAP4 levels in plasma (pMFAP4) reflect
COPD severity were the following: I) to evaluate the asso-
ciation of MFAP4 levels with parameters reflecting disease
severity in a stable COPD cohort; II) to evaluate the vari-
ability of pMFAP4 expression over time in stable COPD; and,
III) to evaluate pMFAP4 variation during and after an acute
exacerbation of COPD (AECOPD).Methods
Ethical considerations
Study protocols were approved by the Regional Scientific
Ethics Committee for Southern Denmark, and oral and writ-
ten informedconsentwereobtained fromthe study subjects.
Stable COPD patients
The patients evaluated in this study were from the Danish
subpopulation of the ECLIPSE cohort (Evaluation of COPD
Longitudinally to Identify Predictive Surrogate End-points;
Clinicaltrials.gov identifier NCT00292552; GSK study code
SCO104960) [14] and were followed up after 3, 6, 9, 12, 18
and 24 months. Briefly, patients with stable COPD, aged
40e75 years and with a smoking history of at least 10 pack-
years were enrolled [14]. The measured or estimated clin-
ical outcomeswere FEV1; FVC and FEV1/FVC; a 6-minwalking
test; thepercentage of lowattenuationarea (LAA%); exhaled
carbon monoxide, eCO, with current smoking defined as an
eCO >12 ppm; the modified Medical Research Council
(mMRC) dyspnoea scale; and the BODE index calculated ac-
cording to standards, using the Body Mass Index, Obstruction
Index, Dyspnoea score and Exercise capacity. COPD subjects
were asked about exacerbations 3, 6 and 12 months after
enrolment in the study. In addition, they were contacted by
telephone every month by the study staff and asked about
details of exacerbations during the previous month. Specif-
ically, subjects were asked whether they had been unwell in
the last month, whether they had seen a doctor or been to
hospital and whether they had taken any medication for
exacerbations (oral corticosteroids or antibiotics). The data
were analysed 12 months after enrolment into the study as
described previously [15].
Control subjects
EDTA-plasma samples were obtained from 54 smoking and
52 non-smoking control subjects who were recruited from
1338 S.L. Johansson et al.the blood donor bank at Odense university hospital. The
subjects’ ages, genders and smoking habits were obtained
through the register forms.
Severe acute exacerbation of COPD (AECOPD)
patients
Fifteen AECOPD patients were recruited from September
2012 through June 2013 at the Medical Emergency Ward,
Odense University Hospital. The inclusion criteria were an
age of between 40 and 80 years; FEV1 < 80% and FEV1/
FVC < 0.7; at least 1 exacerbation in the year prior to in-
clusion; and a smoking history of at least 10 pack-years. The
most important exclusion criteria were pneumonia
confirmed by chest X-ray, diagnosis with other respiratory
disease, congestive heart disease with an ejection fraction
of <40%, or recent cancer. A full list of inclusion and
exclusion criteria and of therapeutic treatment is shown in
the supplementary methods sections. Blood samples were
collected at inclusion (day 0), on days 1, 3e5, 6e8, 9e11,
and at 4 weeks and 3 and 6 months after inclusion.
Measurement of MFAP4 in plasma (pMFAP4)
pMFAP4 was measured by a modified AlphaLISA immuno-
assay from Perkin and Elmer using two monoclonal anti-
bodies, HG-HYB 7-14 and HG-HYB 7-18, as previously
described [8]. One unit/mL of MFAP4 corresponds to 38 ng/
mL of MFAP4 in serum.
Immunohistochemical staining of transplant lung
tissue
The immunohistochemical staining for microfibrillar-
associated protein 4 (MFAP4) was performed on lung
parenchymal paraffin embedded tissue from non-
emphysematous control donor lungs and from transplant
recipients with severe emphysema caused by cigarette
smoking or a1-antitrypsin deficiency. The tissue samples
were acquired from the transplant biobank at Department
of Pathology, Rigshospitalet, Copenhagen University Hos-
pital. Immunohistochemical staining was carried out using
an anti-MFAP4 (HG-HYB 7-14) antibody as described previ-
ously [8].
Statistical methods
pMFAP4 was normally distributed in all of the subgroups of
the COPD patients and controls. The comparisons between
two groups were performed using a t-test for groups with
equal variances, and the comparisons between three or
more groups were done using indicator variables in uni-
variate and multivariate linear regression models. A
Spearman’s correlation analysis and multiple linear re-
gressions were used when analysing the association be-
tween the dependent variable (pMFAP4) and the continuous
explanatory variables. The covariates and interaction terms
in multiple linear regressions were tested by subsequently
reducing the model by backward elimination followed by a
comparison of Akaikes Information Criteria and by using athreshold of p < 0.2. The best reduced model included age,
gender and the dichotomous variable exhaled carbon
monoxide of >12 ppm as covariates.
The relationship between pMFAP4 and exacerbations
was evaluated in 3 different ways: 1) as a continuous var-
iable with numbers of exacerbations; 2) as a categorical
variable of “frequent exacerbator” defined by 2 exacer-
bations the year prior to inclusion [14]; and, 3) a categor-
ical variable defined as an exacerbation between baseline
and 3 month follow-up.
The variability in pMFAP4 over time was assessed in a
mixed effect model adjusted for age, current smoking and
gender, with inclusion levels as references. The within-
patient and between-patient variance was estimated by
allowing the intercept to vary at random. All statistical
analyses were performed with STATA version 11.Results
pMFAP4 in patients with stable COPD at baseline
Of the 91 patients included in the Danish sub-cohort of the
ECLIPSE [16], baseline blood samples were available from
76 of the stable COPD patients. Four patients were
excluded from this study due to a diagnosis of cancer during
the study period, and 3 patients provided insufficient in-
formation about smoking during the follow-up. The baseline
characteristics of the included cohort divided into smoking
and non-smoking COPD patients are shown in Table 1. The
current smoking COPD patients had non-significantly lower
pMFAP4 relative to the ex-smoking COPD patients
(p Z 0.2). Age was positively associated with pMFAP4
(b Z 0.09, p Z 0.03) and women had a higher pMFAP4
relative to men, 8.7  2.6 U/mL versus 7.5  2.3 U/mL,
respectively (p Z 0.046).pMFAP4 in control subjects
pMFAP4 was not significantly different between COPD sub-
jects and control subjects. However, the control population
was younger than the COPD population, with a mean age of
46  12 years in the cigarette smoking controls versus
41  14 years in the non-smoking controls. Age was posi-
tively associated with pMFAP4 (b Z 0.038, p Z 0.04), and
pMFAP4 was significantly lower in the cigarette smoking
controls relative to the non-smoking controls, 6.8  2.2 U/
mL versus 8.4  2.5 U/mL, respectively (pZ 0.003). There
was no difference in pMFAP4 between females and males in
the control group, 7.5  2.6 versus 7.6  2.5, respectively
(p Z 0.8).Association between pMFAP4 and severity of
disease in patients with stable COPD at baseline
The investigated patients were distributed with 0% GOLD I,
42% GOLD II, 47% GOLD III, and 11% GOLD IV, respectively.
Univariate analysis was used to determine the effects of
age (b Z 0.093, p Z 0.01), male gender (b Z 1.2,
p Z 0.05) and eCO > 12 ppm (b Z 0.90, p Z 0.1), and
Table 2 Association between pMFAP4 and clinical outcomes in
r p b-coeff
GOLD 0.19 0.11 1.09
mMRC 0.34 0.004 1.08
FEV1 (L) 0.37 0.02 0.89
FEV1/FVC 0.05 0.7 0.033
DFEV1 (mL) 0.24 0.04 0.0048
6MWD (m) 0.26 0.03 0.0051
BODE 0.24 0.04 0.42
LAA% 0.04 0.7 0.02
Exacerbation 1 0.46 0.16 0.43
Exacerbation þ1 0.24 0.017 0.11
Exacerbation þ3 0.06 0.6 0.04
Spearman correlations and multivariate linear regressions with MFAP
covariates age, gender and exhaled carbon monoxide (eCO) >12 ppm
GOLD: Global initiative for Obstructive Lung Disease (GOLD) grade,
expiratory volume in 1 s, FVC: forced vital capacity, DFEV1: FEV1 re
bronchodilator FEV1 and FVC (obstruction index), 6MWD: 6 min wal
(FEV1/FVC), dyspnea score (mMRC), exercise capacity (MWD), LAA%:
computer tomography scan. Exacerbation 1: within the month befo
a Effects on clinical outcomes are per increase of 1 standard devia
multiple regressions.
Table 1 Basic characteristics stratified by smoking in
stable COPD patients.
COPD
smokers
(21)
COPD
ex-smokers
(48)
COPD
total (69)
MFAP4 (U/mL) 7.7  2.4 8.5  2.5 8.2  2.5
Age (years) 61  7 62  7 62  7
Female (%) 38 60 53
Carbon monoxide
(ppm)*
24 (21) 4 (4.5) 7 (19)
Pack-years* 46 (25) 38 (16) 40 (20)
FEV1 (% pred.) 51  17 49  16 50  16
FVC (% pred.) 89  20 85  20 86  20
FEV1/FVC 0.45  0.11 0.48  0.13 0.47  0.12
DFEV1 (mL) 178  152 152  111 152  111
6MWD (m) 418  124 422  112 421  117
mMRC* 1 (1) 1 (1) 1 (1)
BMI 25.0  5.2 26.9  4.2 26.2  4.7
Fat free mass
(kg/m2)
17.3  3.1 17.5  2.8 17.4  2.9
BODE index* 2 (4) 3 (3) 3 (3)
LAA% 14  11 19  15 17  14
Values are presented as the mean  standard deviation, except
for *values presented as the median (interquartile range). One
pack-year Z 20 cigarettes daily, or 50 g of tobacco weekly in
one year. MFAP4: Microfibrillar-associated protein 4, FEV1 (%
pred.): post-bronchodilator forced expiratory volume in 1 s in
percent of predicted value, FVC (% pred.): post-bronchodilator
forced vital capacity in percent of predicted value, FEV1/FVC:
ratio between post-bronchodilator FEV1 and FVC (obstruction
index), DFEV1: FEV1 reversibility after bronchodilator, 6MWD:
6 min walking distance, mMRC: modified Medical Research
Council score, BMI: Body mass index, BODE index: body mass
index, obstruction index (FEV1/FVC), dyspnoea score (mMRC),
exercise capacity (MWD), LAA%: percentage of low attenuation
area (<950 Hounsfield units) in computer tomography scan.
Figure 1 Plasma microfibrillar-associated protein 4 (pMFAP4)
stratified by the modified Medical Research Council (mMRC)
dyspnoea score.
MFAP4 variation in chronic obstructive pulmonary disease 1339multiple linear regressions with pMFAP4 as response vari-
able were then corrected for the identified covariates.
Multiple linear regressions showed significant positive
associations between pMFAP4 and the GOLD grade, modified
Medical Research Council score and BODE index. Negative
associations were found with the 6-min walking distance
(p Z 0.04) and bronchodilator-induced reversibility
(p Z 0.02) (Table 2). The Spearman correlation analyses
were supported by the outcomeof the linear regressionswith
the exception of the insignificant correlation between
pMFAP4 and the GOLD grade (Table 2). The association with
the highest level of significance was found between the
mMRC score and pMFAP4 (Fig. 1). Neither the tissue density
measured as the percentage of low attenuation area (LAA%)
nor the presence of exacerbations of disease 1 month beforestable COPD patients.
CI p Effecta
2.26:1.92 0.01 0.23
0.50:1.66 <0.0001 0.40
2.0:0.17 0.1
0.081:0.016 0.2
0.0088:0.00082 0.02 43
0.010:0.0003 0.04 30
0.14:0.70 0.004 0.74
0.024:0.065 0.4
2.12:1.26 0.6
0.52:0.75 0.7
1.23:1.16 0.9
4 as the dependent variable. The regressions were adjusted for
CI: 95% Confidence Interval.
mMRC: modified Medical Research Council score, FEV1: forced
versibility after bronchodilator, FEV1/FVC: ratio between post-
king distance, BODE index: body mass index, obstruction index
percentage of low attenuation area (<950 Hounsfield units) in
re, þ1: within the month after; þ3: within three months after.
tion of pMFAP4 and assessed using the coefficient resulting from
Figure 2 Variability of plasma microfibrillar-associated pro-
tein 4 (pMFAP4) in stable COPD. 3M: 3 months, 6M: 6 months,
12M: 12 months, 18M: 18 months, 24M: 24 months follow-up.
1340 S.L. Johansson et al.nor 1 or 3months after inclusionwere significantly associated
to pMFAP4 measured at inclusion.
Variability of pMFAP4 in patients with stable COPD
at baseline
The variability of pMFAP4 over time was evaluated in a
mixed effects model adjusted for age, gender and current
smoking. The within-patient standard deviation of pMFAP4
was 1.4 U/mL, and the between-patient standard deviation
was 2.0 U/mL. The within-patient variance made up 32% of
the total variance in pMFAP4. The two-year variation in
pMFAP4 in patients with stable COPD at baseline is depicted
in Fig. 2. An assessment of repeatability between baseline
pMFAP4 and the 3 month follow-up showed that pMFAP4
varied less than 25% in 83% of the patients.
pMFAP4 in severe acute exacerbation of COPD
(AECOPD) patients
Fifteen patients were enrolled during an admission to the
hospital due to AECOPD. These patients were not aTable 3 Basic characteristics stratified by time point in AECOP
Inclusion 4 week follow
Age (years) 66  8
Current smoking (%) 36%
Pack-years* 60 (34)
mMRC* 5 (0) 3.5 (1)
FEV1 (% pred.) 30  11 36  12
FVC (% pred.) 59  9 60  17
FEV1/FVC 0.48  0.18 0.47  0.16
pMFAP4 (U/mL) 10.6  3.8 14.7  7.3
sSP-D (ng/mL)* 1047 (847) 1446 (1002)
WBC (1000/mL)* 10.2 (5.8) 7.6 (2.9)
CRP* mg/L 13 (39) 7.5 (13.5)
Values are presented as the mean  standard deviation, except for
yearZ 20 cigarettes daily for one year, or 50 g tobacco weekly for on
FEV1 (% pred.): forced expiratory volume in one second in percent of p
predicted value, FEV1/FVC: ratio between post-bronchodilator FEV
associated protein 4, sSP-D: serum surfactant protein D, WBC: whitesubpopulation of the ECLIPSE cohort but comprised a
separate population of acute COPD patients. One patient
was excluded after 4 weeks due alcohol misuse. Fourteen
patients were eligible for the entire 6 months follow-up.
Characteristics of the patients are presented in Table 3.
pMFAP4 was found to be significantly higher at 4 weeks
(b Z 3.6, p < 0.00001), 3 months (b Z 3.0, p < 0.00001)
and 6 months (b Z 3.4, p < 0.00001) relative to inclusion
(Fig. 3A). The same pattern was observed for the serum
levels of surfactant protein D (sSP-D), where the logarith-
mically transformed levels (lnSP-D) at 4 weeks (b Z 0.28,
p Z 0.008) and 6 months (b Z 0.24, p Z 0.02) were
significantly higher relative to inclusion. In addition, a
decline in sSP-D was seen in the first 10 days after inclusion,
with significantly lower sSP-D around day 10 relative to
inclusion (b Z 0.39, p < 0.0001) (Fig. 3B). The opposite
trend was seen in white blood cell counts (WBC), with an
increase in the logarithmically transformed levels (lnWBC)
peaking around day 10 after inclusion (bZ 0.21, pZ 0.02)
followed by a decrease in WBC with significantly lower
values at 4 weeks (b Z 0.30, p < 0.0001), 3 months
(b Z 0.37, p < 0.0001) and 6 months (b Z 0.39,
p < 0.0001) (Fig. 3C).
Localisation of MFAP4 in the lung
Immunohistochemical staining verified the previous obser-
vation that MFAP4 is located in the alveolar septae and in
vessels of the lung parenchyma both in the non-diseased
lung [9] and likewise in the emphysematous lung tissue
(Fig. 4). MFAP4 was further highly expressed in the sub-
mucosal layer of the bronchial tissue (not shown). The
MFAP4-immunostaining appeared further extended into the
adventitia in the emphysematous tissue when compared
with non-emphysematous tissue (Fig. 4).Discussion
The role of MFAP4 in COPD pathogenesis is unknown. MFAP4
is found with relatively high expression in the lung [8] andD patients.
-up 3 month follow-up 6 month follow-up
3.5 (1.5) 4 (2)
42  21 39  17
70  19 68  13
0.48  0.18 0.46  0.16
13.2  6.3 14.1  6.3
1277 (1708) 1284 (1170)
7 (3.1) 7.7 (2.3)
1 (12) 4 (6)
*data presented as the median (interquartile range). One pack-
e year. mMRC: Modified Medical Research Council dyspnoea scale,
redicted value, FVC (% pred.): forced vital capacity in percent of
1 and FVC (obstruction index), pMFAP4: plasma microfibrillar-
blood cell count, CRP: C-reactive protein.
Figure 3 Variability of markers in AECOPD. Variability of A)
plasma microfibrillar-associated protein 4 (pMFAP4), B) serum
surfactant protein D (sSP-D) and C) white blood cell counts
(WBC), from admission (Day 0) for acute exacerbation
(AECOPD) and at various intervals during 120 days follow-up.
MFAP4 variation in chronic obstructive pulmonary disease 1341binding properties to extracellular matrix fibres and smooth
muscle cells have previously motivated hypotheses for roles
in elastic fibre assembly and in pulmonary emphysema
development [10,17]. The present study set out to inves-
tigate if MFAP4 variation might reflect COPD severity and
the potential utility of plasma MFAP4 (pMFAP4) as a
biomarker for clinical outcomes in COPD.
The Danish subgroup of the ECLIPSE cohort of stable
COPD patients was examined and we found that pMFAP4
was higher with increasing age and female gender and
depressed by current cigarette smoking as demonstrated
previously in a population based cohort [18]. We found
statistically significant negative associations between
pMFAP4 and the 6-min walking distance and FEV1 bron-
chodilator reversibility and positive associations were
found with GOLD grade, mMRC dyspnoea scale and thecomposite BODE index. All these associations are previously
demonstrated markers of severity of COPD associated with
morbidity and mortality [19,20] and the data indicated that
increased pMFAP4 reflects disease severity. The pMFAP4
levels varied less than 25% between baseline and 3 month
follow-up in 83% of the patients with stable COPD at
baseline. In contrast, pMFAP4 was significantly increased at
a stable level 1 month after hospitalization although it
seemed unaffected during the first days of an acute exac-
erbation of disease.
The elastin degradation product desmosine has previ-
ously been reported to be present at higher levels in GOLD
II than in GOLD IV [5], and the rates of lung function decline
are higher in GOLD II and III relative to GOLD IV, supporting
a higher degree of disease activity in moderate-severe
COPD relative to very severe COPD [21]. Such observa-
tions for desmosine variation originally prompted a working
hypothesis that pMFAP4 would be decreased in severe dis-
ease. However, we found the highest levels of pMFAP4 in
the stable patients with the most severe clinical outcomes.
The observed pMFAP4 variation may however just reflect
that there were only 8 subjects with very severe COPD in
the present study and that we have predominantly inves-
tigated systemic variation of pMFAP4 in GOLD II and III. A
limitation the present study is further that we did not
compare the pMFAP4 variation to that of desmosine.
We found that cigarette smoking is associated with
reduced levels of pMFAP4. A higher pMFAP4 was also found
in ex-smoking COPD subjects compared with current
smokers, but the difference was not significant. The vari-
able “exhaled CO > 12 ppm” had a larger effect on pMFAP4
than “current smoking”, and there was no significant as-
sociation between pack-years and pMFAP4. This indicates
an acute effect of cigarette smoking on pMFAP4 levels
contradicting the working conclusion that increased levels
of pMFAP4 reflect disease severity. Active cigarette smok-
ing may thus spur putative associations between pMFAP4
and COPD outcomes. This aspect of pMFAP4 variation war-
rants investigation in larger cohorts stratified into smoking
and non-smoking subjects. Although it is now documented
in two independent studies that systemic MFAP4 is
depressed by tobacco smoking it is currently unknown how
this depression is inferred. We can only speculate this to be
caused by cellular dysfunction as a result of toxins within
cigarette smoke as previously suggested for the pulmonary
marker CC-16 [22].
We estimated associations between pMFAP4 and clinical
outcomes in stable COPD patients and found that one 1
standard deviation increase in pMFAP4 corresponded to a
fall in bronchodilator FEV1 of 43 mL, a fall in 6 min walking
distance of 30 m, an increase in the BODE index of 0.74
units, a 0.23 unit increase in GOLD grade and a 0.40 unit
increase in the mMRC score. The calculations of the mag-
nitudes of the relations, however, warrant confirmation in
larger cohorts with more disease heterogeneity and in
particular with more subjects with very severe disease.
There was no association to lung tissue density and
pMFAP4 therefore may be suggested to reflect bronchitis
related changes in the lung rather than emphysema status
in this study of patients with stable COPD at baseline. Yet,
data describing the change in LAA% with time were not
Figure 4 Localisation of microfibrillar-associated protein 4 (MFAP4) in lung tissue. Anti-MFAP4 antibody (HG-HYB 7-14) staining in
A and B) parenchymal tissue from two anonymous healthy donor lungs, C and D) parenchymal tissue from two explanted lungs with
cigarette smoke-induced emphysema, E and F). parenchymal tissue from two explanted lungs with emphysema due to a1-anti-
trypsin deficiency, non-smoker and ex-smoker, respectively. Original magnification 100. Bars are 300 mm.
1342 S.L. Johansson et al.available and we cannot exclude that pMFAP4 variation
reflects elastic fibre degradation in the lung.
Variability is a highly important aspect in the evaluation
of biomarkers for chronic disease. Immunodetection of
MFAP4 in blood samples has previously been demonstrated
to be highly resistant to pre-analysis handling and storage
conditions [23]. Here we show that the time-dependent
within-patient variability in MFAP4 over 2 years made up
approximately one third of the total variation of pMFAP4 in
COPD patients. There was a small but significant continuous
increase in pMFAP4 over 2 years, which may indicate an
increase in pMFAP4 in association with disease progression.
However, 83% of the COPD patients with stable disease at
baseline had a pMFAP4 variation of <25% within 3 months,
and thus the marker appeared relatively stable over time.
Mean levels of pMFAP4 in the control subjects did not
appear to differ from the mean levels in stable COPD. In
contrast, the mean levels of pMFAP4 appeared to be higher
in the AECOPD cohort relative to the patients with stable
COPD at baseline although only preliminary conclusionsmay be drawn from the comparison as the independent
cohorts were not matched.
The functional role of MFAP4 has yet to be elucidated in
detail, although a role in elastic fibre assembly was
recently suggested [13]. MFAP4 was found to be increased
in pulmonary hypertension [24], and systemic levels were
decreased in stable atherosclerosis [8]. These observations
suggest that MFAP4 is regulated by cardiovascular disease.
The present study thus cannot rule out that the associations
found between pMFAP4 and clinical outcomes in stable
COPD may be secondary to cardiovascular pathology. The
separated analyses of MFAP4 associations to pulmonary or
cardiovascular outcomes warrant confirmation in larger
cohorts with detailed information about cardiovascular
disease.
pMFAP4 increased only slightly during the first 11 days of
acute exacerbations. However, the pMFAP4 levels subse-
quently rose after 4 weeks and remained stable until 6
month follow-up. Systemic SP-D was also lower at inclusion
relative to the stable phase but continued to decrease until
MFAP4 variation in chronic obstructive pulmonary disease 1343days 9e11 after inclusion. After 4 weeks, SP-D also
remained stable until 6 month follow-up. Previous studies
showed increased levels of SP-D at exacerbation [5,25] and
in bacterial pneumonia [26]. In this study, we excluded
patients with pneumonia, which may explain the discrep-
ancy between these observations. The observed decline in
serum SP-D and the increase in white blood cells during the
exacerbation are likely to be caused by glucocorticoid
treatment [27,28].
Limitations of this sub-study include the limited number
of patients and the lack of information about stable pMFAP4
levels before inclusion and we cannot definitively conclude
that pMFAP4 was undisturbed at baseline in AECOPD.
The present study supported that MFAP4 is localised to
elastic fibres in the lungs, in alveolar septae, in pulmonary
vessels and in the submucosal layer of the bronchi in COPD,
as shown previously in non-diseased lung tissue [9]. The
fractional area of elastic fibres in the lungs is decreased in
COPD [29]. In contrast, there may be increased fibrosis and
arterial hyperplasia. These structural changes may all in-
fluence the levels of MFAP4 in the lungs. The present study
was not designed to enable measurement of the MFAP4
expression in the lung tissue and no attempts were made to
quantify the immunostaining.Conclusions
Plasma levels of MFAP4 represent a novel blood marker that
is increased with the severity of stable COPD, and in the
months following an acute exacerbation. The pMFAP4 levels
appeared stable in stable COPD and varied <25% between
baseline and 3 month follow-up in 83% of the patients.
Larger longitudinal studies are warranted to confirm these
findings and the strength of association.Conflict of interests
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